



[Test Update 713](#)

Posted Date 04/09/2020

Effective Date 04/09/2020

Update Type [New Tests](#)

CPT Code 85613, 85732, 85610, 85730, 85300, 85306, 85303

Effective April 9, 2020 MLabs will offer Clotting Hypercoagulation Panel (LASAY(PT7,PTT,DRVVT,HEXAG), PSAGF, PCA, AT3) [CLOT]. See below for more test information.

Collection Instructions: Collect four 2.7 mL sodium citrate tubes (blue top) of whole blood. Invert gently at the tubes at time of collection and ship the specimens to MLabs within three hours of collection. Alternatively, centrifuge the specimen and aliquot the plasma into four plastic vials and freeze within four hours of collection. Ship specimens on dry ice to MLabs.

NOTE: Collection of the blood through lines that have been previously flushed with heparin should be avoided. If the blood must be drawn through a VAD (vascular access device), the line should be flushed with 5 mL of saline and the first 5 mL of blood or six dead space volumes of the VAD discarded.

Please provide clinical history (brief description of the reason for testing, eg. history of recent or remote thromboembolism, family history of hypercoagulability) and a listing of current and recent medications, including oral contraceptives, and anticoagulants.

Analytic Time: 7 Days

Test usage: During a thrombotic risk investigation, the evaluation for presence of a lupus anticoagulant, Antithrombin III activity, Protein C activity, and Protein S Antigen (Free) can help determine a patient's hypercoagulable risk. More comprehensive than the Protein C and S Hypercoagulation panel, this panel includes Protime (PT), Activated Partial Thromboplastin Time (aPTT), Dilute Russell Viper Venom Test (dRVVT), Hexagonal Phospholipid Neutralization Assay, Protein C Activity, Antithrombin III Activity, and Protein S Antigen (Free). Test may include pathologist interpretation of results at an additional charge, and is not indicated for patients receiving anticoagulant therapy, or immediately following an acute thrombotic event. Not included in this panel, but offered in the Thrombotic Risk Profile (PROTH), other tests to be considered as part of an evaluation for a prothrombotic state: Factor VIII Assay, Fibrinogen (clottable), Fibrinogen Antigen, Activated Protein C Resistance, and Plasminogen Activity.

[View PDF](#)